Cessatech A/S

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.

Quotes for Cessatech A/S

Board

CEO

  • Jes Trygved

Chairperson of the Board

  • Martin Olin

Board

  • Charlotte Videbæk
  • Flemming Steen Jensen
  • Rachel Curtis Gravesen
Powered by Modular Finance
*Powered by Modular Finance
Key Numbers
2026-03-31 2025-12-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Number of months that the report spans Q1 3 Months 2025 Q4 3 Months Q3 3 Months Q2 3 Months Q1 3 Months 2024
Total revenue MDKK 0.00 5.72 1.99 -1.24 -1.24 -1.24 2.49
Earnings before interest and tax MDKK -3.76 -14.97 -1.84 -3.97 -3.55 -5.61 -19.05
Profit before tax MDKK -3.78 -14.97 -1.81 -3.98 -3.56 -5.62 -17.72
Net profit MDKK -3.23 -10.90 -0.77 -3.05 -2.79 -4.30 -14.67
Earnings per share DKK -0.17 -0.60 -0.04 -0.16 -0.16 -0.25 -0.85
Dividend per share DKK 0,00 0.00 0.00 0,00 0,00 0,00 0.00
Equity MDKK 9.06 12.16 12.16 13.15 15.95 4.40 8.27
Fixed assets MDKK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible assets MDKK 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Current assets MDKK 10.24 13.19 13.19 15.51 21.13 11.07 15.70
Total asset MDKK 10.44 13.39 13.39 15.71 21.33 11.27 15.90
Long term liabilities MDKK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current liabilities MDKK 1.38 1.23 1.23 2.56 5.38 6.87 7.63
Number of shares DKK 18576437.00 18576437.00 18576437.00 18576437.00 18576437.00 17425094.00 17425094.00
*Compiled data from Millistream